Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Mostafa Faisal Mohammed Saleh: Targeting Plasma Cells to Control Persistent ADAMTS13 Autoantibodies in iTTP
Nov 3, 2026, 20:50

Mostafa Faisal Mohammed Saleh: Targeting Plasma Cells to Control Persistent ADAMTS13 Autoantibodies in iTTP

Mostafa Faisal Mohammed Saleh, Associate Professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored et al., published in Hematology, adding:

“Excited to share our latest report on Daratumumab in immune-mediated thrombotic thrombocytopenic purpura (iTTP)

Exploring the emerging role of plasma cell–targeted therapy in refractory and frequently relapsing iTTP.

Anti-CD38 therapy targets plasma cells responsible for persistent anti-ADAMTS13 autoantibody production.

Six clinical reports (approximately 40 patients): ADAMTS13 response in 75% in the largest multicenter cohort; median response time 26 days.

Promising option for refractory or relapsing iTTP, with generally manageable toxicity.

Biochemical relapse remains a concern. Prospective trials are needed to define its role.”

Title: Daratumumab in immune-mediated thrombotic thrombocytopenic purpura: emerging evidence for plasma cell–targeted therapy

Authors: Mostafa F. Mohammed Saleh, Nourah Alzaidy, Momen Nassani, Ahmed Kotb Abdrabou, Abdulrahman Nasiri, Hazza Alzahrani

Mostafa Faisal Mohammed Saleh

Other posts featuring Mostafa Faisal on Hemostasis Today.